EPCT-05. A PHASE 1/2 STUDY OF AVAPRITINIB FOR KIT- OR PDGFRA-MUTANT PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS

Prognosis for pediatric patients with advanced relapsed/refractory (R/R) solid (including central nervous system [CNS]) tumors is poor; targeted therapies achieve response rates of only ~15%. Germ cell tumors and high-grade glioma (HGG) are the most common with KIT mutations; sarcoma and HGG are the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Chi, Susan, Hsieh, Antony, Foley, Megan, Shi, Hongliang, Swamy, Preethi, Rodstrom, Jill, Rudoltz, Marc
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Translational/Early Phase Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8263205/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noab090.191
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados